Acute Kidney Injury (AKI) is a common and potentially life-threatening condition. AKI affects over 4 million people in the United States with an annual cost of up to $24.0 billion. Despite efforts to develop new therapeutic modalities, current therapeutic options remain very limited.
.jpg)
Eliaz Therapeutics is developing a novel medical device to selectively remove galectin-3 from the bloodstream.
Galectin-3 (Gal-3) is an important mediator and known key driver of organ inflammation and fibrosis in numerous acute and chronic progressive conditions. In critically ill patients, the development of AKI and sepsis is associated with increased plasma Gal-3 levels. When Gal-3 is blocked in animal models, AKI rates significantly decrease and survival increases.
Find out how we have developed the technology to target and remove Gal-3 directly from the bloodstream.
.jpg)
Galectin-3 (Gal-3) is protein that our bodies produce increasingly overtime, due to stress, injury, and aging. This protein has been clinically proven in 3,000 studies to cause a wide range of health issues. Many of the chronic illnesses we, and our loved ones face every day can be traced back to the damages caused by this one protein.
.jpg)
The single-use XGal-3 apheresis column selectively removes Galectin-3 from the body. XGal-3 contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.
